MicroRNA sponges: progress and possibilities.

By Margaret S. Ebert, Phillip A. Sharp. RNA: A publication of the RNA Society, 2010

617 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Development of microRNA therapeutics is coming of age (2014, neutral): “A miRNA sponge uses transgenic overexpression of RNA molecules harboring complementary binding sites to a miRNA of interest to block the function of a given miRNA or a miRNA family (Ebert & Sharp, 2010).”
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, methodology): “In recent years, a method has been described to inhibit miRNA function using synthetic mRNAs containing multiple binding sites for a specific miRNA, called miRNA sponges [232, 233].”
MicroRNAs in human cancer. (2013, background): “Alternatively, “miRNA sponges” have been exploited to reduce miRNA expression in mammalian cells and mouse models by using RNA transcripts expressed from strong promoters containing miRNA-complementary binding sites (reviewed in [ 199 ] ).”
A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? (2011, background): “They are often cloned into viral vectors so that they can be expressed at high levels (Ebert and Sharp, 2010).”
miRNAs in human cancer (2010, neutral): “miRNA-complementary binding sites (reviewed in [181]).”
RNA-based Therapeutics- Current Progress and Future Prospects (2012, background): “Emerging therapeutic strategies to regulate miRNA activity include antisense-miRNA ONs (antagomirs) and RNA competitive inhibitors or decoys (miRNA sponges) (Ebert and Sharp, 2010).”